Placebo: Clinical Trials

43,741 trials of Placebo, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

28049 completed, 4040 terminated, 3796 unknown, 3384 recruiting. 15147 Phase 2, 10863 Phase 3, 8474 Phase 1, 7302 Not applicable, 4451 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	15147	Completed 9236, Terminated 1803, Recruiting 1258, Unknown 1106, Withdrawn 671, Active not recruiting 535, Not yet recruiting 449, Suspended 52, Enrolling by invitation 37
Phase 3	10863	Completed 6759, Terminated 1155, Recruiting 910, Unknown 809, Active not recruiting 565, Withdrawn 331, Not yet recruiting 287, Suspended 28, Enrolling by invitation 19
Phase 1	8474	Completed 6157, Terminated 644, Recruiting 584, Unknown 412, Withdrawn 240, Not yet recruiting 207, Active not recruiting 195, Suspended 21, Enrolling by invitation 14
Not applicable	7302	Completed 4578, Unknown 1111, Recruiting 549, Not yet recruiting 340, Terminated 306, Withdrawn 197, Active not recruiting 154, Enrolling by invitation 50, Suspended 17
Phase 4	4451	Completed 2729, Unknown 635, Terminated 430, Recruiting 278, Withdrawn 162, Not yet recruiting 131, Active not recruiting 70, Suspended 9, Enrolling by invitation 7
Early Phase 1	619	Completed 348, Recruiting 85, Unknown 70, Not yet recruiting 32, Terminated 28, Active not recruiting 24, Withdrawn 22, Enrolling by invitation 6, Suspended 4

Follow Placebo: new trials by email Literature Review of Placebo trials Research Report on Placebo

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Safety Study of CZ10 in Healthy Volunteers Contrast Media, Placebo - Healthy Volunteer Study	Phase 1	Not yet recruiting	Nextrast, Inc.	24	2050-01-01	2024-11-29
Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis Cannabidiol (CBD), Placebo - Schizophrenia Spectrum Disorders, Cannabis Use	Phase 2	Withdrawn	University of Maryland, Baltimore		2050-01-01	2021-04-19
Influence of Fampridine on Working Memory in Healthy Subjects Fampridine SR, Placebo - Working Memory	Phase 2	Withdrawn	Prof. Dominique de Quervain, MD		2040-01-01	2024-12-05
Evaluation of Naloxegol in the Prevention of POI After Cystectomy Naloxégol oxalate, Placebo oral tablet - Bladder Cancer, Cystostomy; Complications	Phase 2	Withdrawn	Institut Paoli-Calmettes		2032-01-01	2026-10-14
Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance Vigabatrin Pill, Placebo oral tablet - Hyperinsulinism, Insulin Resistance	Phase 2	Withdrawn	University of Arizona		2030-04-15	2025-07-30
FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease FGF-1, Placebo - Peripheral Arterial Disease, Stenosis	Phase 1 / Phase 2	Not yet recruiting	Venturis Therapeutics, Inc.	24	2028-10-15	2026-08-19
Terazosin And Metabolic Energetics in Parkinson's Disease Terazosin 5 MG, Placebo - Parkinson's Disease (PD)	Phase 2	Suspended	Ergun Y. Uc	120	2028-07-01	2026-10-09
Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled Trial Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells, Placebo - Spinal Cord Injury, Safety	Phase 2	Not yet recruiting	XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.	60	2028-05-25	2025-11-25
Evaluating the Metabolic Effects of Polylactose: A Novel Prebiotic Polylactose, Placebo - Obesity, Adolescent, Obesity, Childhood	Not applicable	Withdrawn	University of Minnesota		2028-05-01	2025-07-11
RCT: Trazodone vs Quetiapine vs Placebo for Treating ICU Delirium (TraQ) Trazodone, Quetiapine, Placebo - Delirium, Morality	Phase 4	Withdrawn	University of Southern California		2028-03-01	2026-05-04
Pyronaridine in Acute Myeloid Leukemia (AML) Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)	Phase 2	Suspended	Armaceutica, Inc.	200	2028-02-21	2026-10-19
Effect of Ginger on Heavy Menstrual Bleeding in Women With Coagulation Disorders Ginger, Placebo - Women With Coagulation Disorders	Early Phase 1	Not yet recruiting	University of Valladolid	74	2028-02-01	2026-05-19
Sodium Lactate in Severe TBI Sodium Lactate, placebo - Traumatic Brain Injury	Phase 2	Not yet recruiting	University of California, Los Angeles	264	2028-01-10	2026-01-16
Perioperative Esketamine Safety and Efficacy in Reducing Postoperative ENDometriosis PAIN (the ENDPAIN Trial): a Randomized Controlled Trial. Esketamine, Placebo - Endometriosis	Phase 4	Not yet recruiting	Region Skane	1000	2028-01-01	2026-10-19
Effects of Food Intake on Biomarker Activity in Normal Humans Taking Immulina Immulina, Placebo - Viral Diseases	Phase 2	Not yet recruiting	University of Mississippi Medical Center	250	2028-01-01	2026-10-23
Vitamin B6 on Exercise Pressor Reflex on Leg Ischemia-reperfusion Vitamin B6 25 MG, Vitamin B6 50 MG, Vitamin B6 100 MG - Ischemia Reperfusion Injury, Peripheral Artery Disease	Early Phase 1	Not yet recruiting	Milton S. Hershey Medical Center	30	2027-12-01	2026-03-17
Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients. Gemfibrozil, Placebo - Parkinson Disease	Phase 2	Withdrawn	Forest Hills Lab		2027-11-01	2026-08-19
The Effects of Menopausal Status, Isoflavone Supplementation and Training on Cardiometabolic Function Women Red Clover Isoflavone Supplementation, Supervised exercise training, Placebo Supplementation - Menopause, Exercise Adaptation	Not applicable	Not yet recruiting	University of Copenhagen	60	2027-10-15	2026-10-16
Dantrolene in Statin-induced Myopathy Dantrolene, Placebo - Statins Induced Myopathy	Phase 2 / Phase 3	Not yet recruiting	Tanta University	23	2027-10-01	2025-05-13
Oral Fosamprenavir for GERD Fosamprenavir Calcium 700 MG Oral Tablet, Placebo - Refractory Gastroesophageal Reflux Disease, Gastroesophageal Reflux Disease	Phase 2	Not yet recruiting	Medical College of Wisconsin	60	2027-10-01	2026-09-10

Showing 20 of 43741. Sign in to see all of them.

Conditions studied

Diabetes Mellitus, Type 2 (1501) · Obesity (1252) · COVID-19 (900) · Pain (851) · Diabetes Mellitus (751) · Asthma (675) · Alzheimer Disease (661) · Pulmonary Disease, Chronic Obstructive (636) · Inflammation (609) · Depression (601) · Schizophrenia (568) · Depressive Disorder, Major (541) · Overweight (532) · Arthritis, Rheumatoid (495) · Parkinson Disease (468)

Countries

United States (20128) · Germany (4881) · Canada (4876) · United Kingdom (4590) · Spain (3904) · China (3692) · France (3682) · Italy (3287) · Poland (3281) · Australia (2945) · Belgium (2517) · Netherlands (2425) · South Korea (2419) · Japan (2319) · Czechia (2006)

Results publications

PMID 34473343, PMID 37142273, PMID 33687069, PMID 37811711, PMID 38770818, PMID 39356039, PMID 40576086, PMID 32816215, PMID 36005278, PMID 37160401, PMID 25019647, PMID 36526796, PMID 36931693, PMID 39963952, PMID 37230961, PMID 38299639, PMID 35713300, PMID 33283264, PMID 34870800, PMID 36600185, PMID 36601090, PMID 37185961, PMID 28433500, PMID 33127856, PMID 37316690, PMID 37983082, PMID 38767196, PMID 39192350, PMID 28143815, PMID 31606880, PMID 33107592, PMID 33331662, PMID 34611902, PMID 35141873, PMID 37916745, PMID 40603145, PMID 25047021, PMID 31903692, PMID 32734597, PMID 35472672, PMID 38958913, PMID 32998732, PMID 34510411, PMID 35224730, PMID 36375174, PMID 26275429, PMID 33710614, PMID 38979716, PMID 39393433, PMID 40680102

NIH funding

2023 (473), 2017 (365), 2015 (359), 2014 (344), 2018 (332), 2016 (327), 2025 (303), 2019 (281), 2009 (272), 2008 (221), 2005 (71), 2004 (44), UL1RR024150 (28), P30CA015083 (20), P30CA016672 (14)